Abstract:It is becoming more and more apparent that many of the genetic alterations associated with cancer are located in areas that do not encode proteins. lncRNAs are a class of RNAs that do not code for proteins but play a crucial role in maintaining cell function and regulating various cellular processes. By doing this, they have recently introduced what may be a brand-new and essential layer of biological control. These have more than 200 nucleotides and are linked to several diseases; as a result, they have become potential tools for therapeutic intervention. Emerging technologies suggest the presence of mutations on genomic loci that give rise to lncRNAs rather than proteins in a disease as complex as cancer. These lncRNAs play essential parts in gene regulation, which impacts several cellular homeostasis processes, including proliferation, survival, migration, and genomic stability. The leading cause of death in the world today is cancer. Delays in diagnosis and a lack of standard and efficient treatments are the leading causes of the high death rate. Clinically, surgery is frequently used successfully to remove cancers that have not spread, but it is less successful in treating metastatic cancer, which has a drastically lower chance of survival. Chemotherapeutic drugs are a typical therapy to treat the cancer that has spread to other organs. Drug resistance to chemotherapy, however, presents a significant challenge to achieving positive outcomes and is frequently the cause of treatment failure. A substantial barrier to progress in medical oncology is cancer drug resistance. Resistance can develop clinically either before or after cancer treatment. According to this study, lncRNAs influence drug resistance through several different methods. LncRNAs often impact drug resistance by controlling the expression of a few intermediary regulatory variables rather than by directly affecting drug resistance. Additionally, lncRNAs have a variety of roles in cancer medication resistance. Most lncRNAs induce drug resistance when overexpressed; however, other lncRNAs have inhibitory effects. This study provides an overview of the current understanding of lncRNAs, relevance to cancer, and potential therapeutic applications.

LncRNAs in modulating cancer cell resistance to paclitaxel (PTX) therapy

Exploring Specific miRNA-mRNA Axes With Relationship to Taxanes-Resistance in Breast Cancer

Noncoding RNAs and their therapeutics in paclitaxel chemotherapy: Mechanisms of initiation, progression, and drug sensitivity

Microarray Expression Profile of Long Non-Coding RNAs in Paclitaxel-Resistant Human Lung Adenocarcinoma Cells.

Key genes and molecular mechanisms related to Paclitaxel Resistance

LncRNA NONHSAT141924 promotes paclitaxel chemotherapy resistance through p-CREB/Bcl-2 apoptosis signaling pathway in breast cancer

Recent Advances in Elucidating Paclitaxel Resistance Mechanisms in Non-small Cell Lung Cancer and Strategies to Overcome Drug Resistance.

TXNDC17 Promotes Paclitaxel Resistance Via Inducing Autophagy in Ovarian Cancer

Resistance to Intervention: Paclitaxel in Breast Cancer

Mechanistic Involvement of Long Non-Coding RNAs in Oncotherapeutics Resistance in Triple-Negative Breast Cancer

Comprehensive review of LncRNA-mediated therapeutic resistance in non-small cell lung cancer

Long Non-coding RNAs and Drug Resistance.

Progress of long noncoding RNAs in anti-tumor resistance.

Long non-coding RNAs; potential contributors in cancer chemoresistance through modulating diverse molecular mechanisms and signaling pathways

Long Noncoding Rna Ror Regulates Chemoresistance In Docetaxel-Resistant Lung Adenocarcinoma Cells Via Epithelial Mesenchymal Transition Pathway

Long non-coding RNAs as the critical regulators of doxorubicin resistance in tumor cells

Recent progress and the emerging role of lncRNAs in cancer drug resistance; focusing on signaling pathways

The Role of Non-Coding RNAs in Breast Cancer Drug Resistance

Exploring the resistance mechanism of triple-negative breast cancer to paclitaxel through the scRNA-seq analysis

Long non-coding RNA (lncRNA) PVT1 in drug resistance of cancers: Focus on pathological mechanisms

Next Generation Deep Sequencing Identified a Novel Lncrna N375709 Associated with Paclitaxel Resistance in Nasopharyngeal Carcinoma